Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus fermentum d3
- Development stage
- Preclinical
- Lead developer
- University of Tartu
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus fermentum D3 is a specific strain of probiotic bacteria, recently reclassified as *Limosilactobacillus fermentum* D3. It is primarily investigated for its potential therapeutic effects in metabolic disorders, specifically type 2 diabetes and obesity. The strain is hypothesized to modulate the gut microbiota composition, leading to improvements in insulin resistance and glucose metabolism. Clinical research, such as the study NCT05076656 conducted by the University of Naples Federico II, explores how oral administration of this probiotic can induce epigenetic changes and microbiota modifications that benefit host metabolic health. Probiotics like *L. fermentum* D3 are thought to exert their effects by enhancing gut barrier function, producing short-chain fatty acids, and modulating systemic inflammation.
- Other names
- Limosilactobacillus fermentum D3
Beyond the preview
Go deeper on lactobacillus fermentum d3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus fermentum d3.